On June 3, 2021 Seattle Cancer Care Alliance (SCCA) reported the presentations from the organization’s clinicians that will be presented at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from June 4-8, 2021 (Press release, Seattle Cancer Care Alliance, JUN 3, 2021, View Source [SID1234583467]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SCCA clinicians contributed to studies across multiple cancer types addressing the full continuum of cancer care – from prevention to diagnosis to treatment. Presentations will highlight results from trials in Phase 1, CAR T-cell therapy, breast cancer, bladder cancer, non-small cell lung cancer and hematologic cancers. Additionally, there are multiple studies on the impact of the COVID-19 pandemic on cancer diagnosis, clinical care and oncology clinical trials. SCCA clinical researchers also contributed to new findings related to genetic profiling, prostate needle biopsy pathology and precision therapy for salivary gland cancer.

"SCCA is a leader in groundbreaking clinical trials turning scientific discovery into exciting new treatments that often change the way cancer care is delivered," said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance and a former ASCO (Free ASCO Whitepaper) president. "The work being presented by our physician-researchers at ASCO (Free ASCO Whitepaper) 2021 further demonstrates these continued efforts to improve the way patients are treated and advance multidisciplinary cancer care."

More information about SCCA’s presentations and publications at ASCO (Free ASCO Whitepaper) is available at: View Source

Presentation Details:

Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.
Abstract: 10500
SCCA author: Kathryn P. Lowry, MD

Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: Estimates from collaborative simulation modeling.
Abstract: 6562
SCCA author: Kathryn P. Lowry, MD

Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
Abstract: TPS2663
SCCA author: Jennifer M. Specht, MD and David G. Maloney, MD, PhD

Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.
Abstract: 1020
SCCA author: Hannah M. Linden, MD

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
Abstract: 1058
SCCA author: Hannah M. Linden, MD

Case-Based Panel: Optimizing Precision Therapy in Salivary Gland Cancers With a Look at the Future
SCCA speaker: Cristina P. Rodriguez, MD

PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
Abstract: 4518
SCCA author: Petros Grivas, MD, PhD

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
Abstract: 4525
SCCA author: Petros Grivas, MD, PhD

The fluciclovine (FACBC) PET/CT site-directed therapy of oligometastatic prostate cancer (Flu-BLAST-PC) trial.
Abstract: TPS5099
SCCA author: Risa L. Wong, Jonathan L. Wright, MD, MS, Heather H. Cheng, MD, PhD and Evan Y. Yu, MD

Clinical accuracy of information extracted from prostate needle biopsy pathology reports using natural language processing.
Abstract: 1557
SCCA author: Risa L. Wong and John L. Gore, MD, MS, FACS

Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.
Abstract: 3130
SCCA author: Petros Grivas, MD, PhD

Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.
Abstract: 5020
SCCA author: Michael T. Schweizer, MD, Evan Y. Yu, MD and Colin C. Pritchard, MD, PhD

Case Based Panel: Optimizing Urothelial Cancer Management From Organ-Confined to Metastatic Disease: A Multidisciplinary Approach
SCCA Moderator/Chair: Evan Y. Yu, MD

Oral Session: Germline Genetic Testing for Prostate Cancer
SCCA Discussant: Colin C. Pritchard, MD, PhD

CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
Abstract: 7532
SCCA author: Jordan Gauthier, MD, MSc, Mazyar Shadman, MD, MPH, David G. Maloney, MD, PhD and Cameron J. Turtle, MBBS, PhD, FRACP, FRCPA

Efficacy of clinical breast examination in chest-irradiated female survivors of childhood Hodgkin lymphoma (HL).
Abstract: 10028
SCCA author: Janie M. Lee, MD, MSc

Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
Abstract: 11523
SCCA author: Michael J. Wagner, MD

Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.
Abstract: 9517
SCCA author: Paul Nghiem, MD, PhD

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Abstract: 9007
SCCA author: Christina S. Baik, MD, MPH

Oral Session: Emerging Trends in Radiation for Localized Lung Cancers
SCCA discussant: Ramesh Rengan, MD, PhD

Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.
Abstract: TPS3147
SCCA author: John A. Thompson, MD

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.
Abstract: 3006
SCCA author: Ryan C. Lynch, MD

Education Session: COG Perspective on the Impact of COVID-19 on Pediatric Oncology Clinical Trials and Implications for the Future
SCCA speaker: Douglas S. Hawkins, MD

Poster Discussion Session: COVID-19 and Cancer: Learning As We Go Along
SCCA discussant: Petros Grivas, MD, PhD

Cancer diagnosis and adverse financial events: Evidence from credit reports.
Abstract: 6504
SCCA author: Veena Shankaran, MD, MS

Choosing Wisely: Selecting the Right Population at the Right Time for DNA-Damaging Therapy
SCCA discussant: Elizabeth M. Swisher, MD